BioSpace News Archive

FDA

ViiV Healthcare’s 2-Drug Combo for HIV Approved by FDA

The U.S. Food and Drug Administration (FDA) approved ViiV Healthcare’s Dovato, a once-a-day, single-tablet combination of dolutegravir (DTG) and lamivudine (3TC) for HIV-1 in adults who had not received treatment before.

April 9, 2019
·
3 min read
·
Mark Terry
Policy

PhaseBio Receives FDA Breakthrough Therapy Designation and Licenses GLP-1 Analog to ImmunoForge

PhaseBio Pharmaceuticals, based in Malvern, Penn. and San Diego, announced that its antiplatelet drug PB2452 had received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA).

April 9, 2019
·
3 min read
·
Mark Terry
Business

Polyphor appoints Gökhan Batur as Chief Commercial Officer

Polyphor AG, a clinical stage, Swiss biopharmaceutical company focused on the discovery and development of antibiotics and immuno-oncology compounds announced the appointment of Gökhan Batur to the newly created position of Chief Commercial Officer.

April 9, 2019
·
3 min read
Business

Out From Under Novartis, Alcon Is Its Own Company Now

Alcon CEO says the company is “poised to achieve sustainable growth and create long-term shareholder value as a standalone company.”

April 9, 2019
·
3 min read
·
Alex Keown
Job Trends

Biopharma Incubators and Accelerators Play a Significant Role in Creating Regional Growth

Life science incubators and accelerators play a highly significant role in the industry and may be the key for regional growth, a new report shows.

April 9, 2019
·
2 min read
·
Alex Keown
Job Trends

Amidst Massive Global Job Cuts, Bayer Expands in Boston

At the same time that Bayer AG announced it was planning to eliminate about 4,500 jobs in Germany, it is adding about 150 jobs over the next three years in Massachusetts.

April 9, 2019
·
2 min read
·
Mark Terry
Policy

A*STAR scientists discover two distinct types of macrophages within interstitial tissues

The distinct roles of these immune cells opens the possibility of new treatments for human inflammatory diseases

April 9, 2019
·
5 min read
Business

New Express Scripts Program Caps Insulin Costs for 30-Day Supplies at $25

The new program will ensure eligible people with diabetes in participating plans pay no more than $25 for a 30-day supply of insulin.

April 9, 2019
·
3 min read
·
Alex Keown
Deals

Pharming Group announces completion of minority investment in BioConnection BV

Pharming has acquired its shareholding through the conversion of €2.5 million of existing credits and €1.6 million of new cash subscription for a total of €4.1 million in BioConnection shares, plus additional shares acquired from existing investors.

April 9, 2019
·
5 min read
Deals

Medigene AG: Medigene sells remaining rights and inventories of Veregen® to Aresus Pharma

Aresus takes over Veregen® business including API stock and intends to invest in expanding Veregen® into indications and markets

April 9, 2019
·
4 min read